SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs

Expert Review of Clinical Pharmacology

Volumn 10, Issue 4, 2017, Pages 429-442

  Singh, Awadhesh Kumar ^a   Singh, Ritu ^a  

^a GD Hospital and Diabetes Institute   (India)

Author keywords

Cardiovascular outcome trial; DPP 4 inhibitors; GLP 1 receptor agonists; major adverse cardiovascular events; SGLT 2 inhibitors

Indexed keywords

ALOGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; LIXISENATIDE; SAXAGLIPTIN; SEMAGLUTIDE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; VILDAGLIPTIN;

CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; REVIEW; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; MYOCARDIAL INFARCTION; STROKE;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; STROKE;

EID: 85015883126     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2017.1287562     Document Type: Review

References (51)

1. Center for Drug Evaluation and Research. Guidance for industry diabetes mellitus:evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008; cited 2016 Sep30. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
2. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. cited 2016 Sep 30. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf
3. Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110(6):826–833.• This meta-analysis showed significant benefit in CV outcomes with DPP-4 inhibitors.
4. Monami M, Ahrén B, Dicembrini I, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk:a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(2):112–120.• Another meta-analysis showed significant benefit in CV outcomes with DPP-4 inhibitors.
5. Engel SS, Golm GT, Shapiro D, et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus:a pooled analysis. Cardiovasc Diabetol. 2013;12:3.
6. McInnes G, Evans M, Del Prato S, et al. Cardiovascular and heart failure safety profile of vildagliptin:a meta-analysis of 17 000 patients. Diabetes Obes Metab. 2015;17(11):1085–1092.
7. Iqbal N, Parker A, Frederich R, et al. Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus:pooled analysis of 20 clinical trials. Cardiovasc Diabetol. 2014;13:33.
8. White WB, Pratley R, Fleck P, et al. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. Diabetes Obes Metab. 2013;15(7):668–673.
9. Rosenstock J, Marx N, Neubacher D, et al. Cardiovascular safety of linagliptin in type 2 diabetes:a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2015;14:57.
10. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patientswith type 2 diabetes mellitus. N Engl J Med. 2013;369:1317–1326.•• First CVOT to show CV neutrality with saxagliptin.
11. White WB, Cannon CP, Heller SR, et al. EXAMINE:alogliptinafter acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–1335.•• One of first CVOT to show CV neutrality with alogliptin in patients with acute coronary syndrome.
12. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232–242.•• Sitagliptin CVOT suggesting CV neutrality and no signal of heart failure.
13. Monami M, Dicembrini I, Mannuci E., Dipeptidyl peptidase-4 inhibitors and heart failure:a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24(7):689–697.
14. Wu S, Hopper I, Skiba M, et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes:meta-analysis of randomized clinical trials with 55,141 participants. Cardiovasc Ther. 2014;32(4):147–158.
15. Weir DL, McAlister FA, Senthilselvan A, et al. Sitagliptin use in patients with diabetes and heart failure:a population-based retrospective cohort study. JACC Heart Fail. 2014;2(6):573–582.
16. Kim C, Glynn RJ, Liu J, et al. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes:a cohort study. Acta Diabetol. 2014;51(6):1015–1023.
17. Yu OH, Filion KB, Azoulay L, et al. Incretin-based drugs and the risk of congestive heart failure. Diabetes Care. 2015;38(2):277–284.
18. Scirica BM, Braunwald E, Raz I, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus:observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014; 130(18):1579–1588.•• Subgroup analysis of SAVOR TIMI found significantly increased heart failure in certain subgroups of patients.
19. Briefing Material. NDA 22350:saxagliptin (Onglyza). NDA 200678:saxagliptin/Metformin (Kombiglyze XR). April 2015; cited 2016 Sep30. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolic-DrugsAdvisoryCommittee/UCM442060.pdf• FDA analysis of SAVOR TIMI and vote regarding CV safety of saxagliptin.
20. EMDAC Briefing Document Cardiovascular Outcomes Trial EXAMINE/NDAs 022271, 022426, & 203414 Nesina (alogliptin), Oseni (alogliptin/pioglitazone), & Kazano (alogliptin/metforminHCl). 2015; cited 2016 Sep30. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM442062.pdf• FDA analysis of EXAMINE and vote regarding CV safety of alogliptin.
21. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes on alogliptin versus placebo from the EXAMINE trial. Lancet. 2015;385:2067–2076.• Post hoc subgroup analysis of alogliptin in EXAMINE.
22. McGuire DK, Van Dewerf F, Armstrong PW, et al.; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus:secondary analysis of arandomized clinical trial. JAMA Cardio. 2016; 1(2):126–135.• Post hoc subgroup analysis of sitagliptin in TECOS.
23. Scirica BM. The safety of dipeptidyl peptidase 4 inhibitors and the risk for heart failure. JAMA Cardiol. 2016;1(2):123–125.
24. cited Sep 30, 2016. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM493965.pdf•• FDA put a labelling of heart failure risk with saxagliptin and alogliptin in patients with pre-existing heart or kidney disease.
25. McMurray JJ, Ponikowksi P, Bolli GB, et al. Vildagliptin in Ventricular Dysfunction Diabetes Trial (VIVIDD). Eur J Heart Fail. 2013;12(suppl):1.• Vildagliptin studied in patients with NYHA Class I-III heart failure and found no harm.
26. https://clinicaltrials.gov/ct2/show/NCT01897532
27. Marx N, Rosenstock J, Kahn SE, et al. Design and baseline characteristics of the CARdiovascular outcome trial of LINAgliptin versus glimepiride in type 2 diabetes (CAROLINA®). Diab Vasc Dis Res. 2015;12(3):164–174.
28. Salsali A, Kim G, Woerle HJ, et al. Cardiovascular safety of empagliflozin in patients with type 2 diabetes:a meta-analysis of data from randomized placebo-controlled trials. Diabetes Obes Metab. 2016;18(10):1034–1040.
29. cited 2016 Sep 30. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM334550.pdf
30. Sonesson C, Johansson PA, Johansson E, et al. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories:a meta-analysis. Cardiovasc Diabetol. 2016;15:37.
31. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.•• First antidiabetic agent empagliflozin to show robust reduction in CV endpoints.
32. Ratner R, Han J, Nicewarner D, et al. Cardiovascular safety of exenatide BID:an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol. 2011;10:22.
33. MacConell L, Gurney K, Malloy J, et al. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes:an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes. 2015;18(8):241–253.
34. cited 2016 Sep 30 www.sanofi.co.uk/l/gb/en/download.jsp?file=1B4E8D41-8F6C-4399-8C64…pdf
35. Caterson ID, Bain SC, Gross J, et al. Cardiovascular safety of liraglutide:pooled analysis of major adverse cardiovascular events across weight management and type 2 diabetes development programs. Circulation. 2015;132(Suppl_3/A12630).
36. Ferdinand KC, Botros FT, Atisso CM, et al. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes:a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol. 2016 Feb 24;15:38.
37. Fisher M, Petrie MC, Ambery PD, et al. Cardiovascular safety of albiglutide in the Harmony programme:a meta-analysis. Lancet Diabetes Endocrinol. 2015;3(9):697–703.
38. Pfeffer MA, Claggett B, Diaz R, et al. ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257.•• First CVOT trial with GLP-1RA published with lixisenatide and found to achieve CV neutrality.
39. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.•• This trial of GLP-1RA liraglutide showing significant reduction on several CV end points.
40. Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844.•• Results with once-weekly GLP-1RA semaglutide showing significant reduction in 3P-MACE.
41. 2016 Sep 30. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM508422.pdf
42. Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction:a randomized clinical trial. JAMA. 2016;316(5):500–508.• Liraglutide studied in patients with advanced heart failure.
43. Jorsal A. Effect of liraglutide, a glucagon-like peptide-I analogue, on left ventricular function in chronic heart failure patients with and without diabetes:the LIVE study. Eur Soc Cardiol (ESC) Heart Fail. 2016;cited 2016 May22. Presentation 599. Florence, Italy
44. https://clinicaltrials.gov/ct2/show/NCT02918591
45. https://clinicaltrials.gov/ct2/show/NCT02862067
46. https://clinicaltrials.gov/ct2/show/NCT02728453
47. https://clinicaltrials.gov/ct2/show/NCT02653482
48. Faillie JL, Yu OH, Yin H, et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176(10):1474–1481.• This cross sectional study found increase in acute gall bladder disease with GLP-1RAs
49. Zhang L, Krzentowski G, Albert A, et al. Risk of developing retinopathy in diabetes control and complications trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care. 2001;24(7):1275–1279.
50. Ferrannini G, Hach T, Crowe S, et al. Energy balance after sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1730–1735.
51. Frías JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8):a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016 Sep 15; pii:S2213-8587(16)30267-4. Epub ahead of print. 10.1016/S2213-8587(16)30267-4• First RCT of combined GLP-1RA with SGLT-2I, showing incremental lowering of blood glucose.